

Retrospective Evaluation of Intravenous Immunoglobulin Use in Adult Hematology Practice

Dr. Istemi Serin

Introduction: Intravenous immunoglobulin (IVIGs) preparations, which are used in the treatment of many immune-based diseases, also have an important place in hematology practice. It is an important treatment option with many different immunoregulatory roles.

Material and Method: There is a limitation of its use on adult patients due to the lack of retrospective data. In our study, the retrospective usage indications, responses and rates of IVIG preparations evaluated in our Hematology Clinic and used in various indications between January 2010 and January 2020 were attempted to be put forth. Our targets for treatment responses were as follows: For immune thrombocytopenia, the platelet count target was $30000 \times 10^3/\mu\text{L}$ and above; no hospitalization need for secondary hypogammaglobulinemia; no replacement need for hemolytic anemia after IVIG and a hemoglobin level above 8 g/dl.

Results: When 166 patients were examined in total, 66 were diagnosed with immune thrombocytopenic purpura (ITP) (39.8%) and 19 chronic lymphocytic leukemia (CLL) (11.4%). There were emergency indications for all patients with thrombocytopenia before getting a primary diagnosis. The number of patients who used IVIG before getting a primary diagnosis was 79 (47.6%), 41 of whom (51.9%) were diagnosed with immune thrombocytopenic purpura in follow up. The expected response was 36.1% with 60 patients within the entire patient group. With further examination performed after emergency usage, the diagnoses received by the patients were revealed. The response was 58.5% with 24 patients in whom IVIG was used under emergency conditions and deep thrombocytopenia before getting a primary diagnosis and were diagnosed with ITP after further examinations.

Discussion and Conclusion: IVIG products stand out with a wide range of effective usages and are frequently preferred. Our study contributes to the literature retrospectively with revealing our patients' data. Content

standardization, disease distributions and different doses of glucocorticosteroids used beside IVIGs in our study restricted the statistical evaluation retrospectively. It is important in terms of transferring experience and revealing data.

REFERENCES

1. Zülfikar B, Koç B. Use of intravenous immunoglobulin in pediatric practice. *Turk Pediatri Ars.* 2014; 49(4): 282-288. Published 2014 Dec 1.
2. Benbrahim O, Viillard JF, Choquet S, et al. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. *Eur J Haematol.* 2018; 101(1): 48-56.
3. Evers D, Zwaginga JJ, Tijmensen J, et al. Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization. *Haematologica.* 2017; 102(1): 52-59.
4. Singhal D, Kutyna MM, Chhetri R, et al. Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. *Haematologica.* 2017; 102(12): 2021-2029.
5. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in *Blood Adv.* 2020 Jan 28; 4(2): 252]. *Blood Adv.* 2019; 3(23): 3829-3866.

Istanbul Training and Research Hospital, University of Health Sciences

Copyright: ©2021 Istemi Serin This work is partly presented in 27th World Congress on Pharmacovigilance and Clinical Trials on October 21-22, 2020 | Frankfurt, Germany

Correspondence: Istemi Serin, Istanbul Training and Research Hospital, University of Health Sciences, Turkey

Received: December 3, 2021, Accepted: December 11, 2021, Published: December 25, 2021



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com